Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  nintedanib
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1199.52, NCI-2014-02486, 2012-000095-42, NCT02149108
Pegylated Liposomal Doxorubicin Hydrochloride and Nintedanib in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, Fallopian Tube, or Recurrent Metastatic Endometrial Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN10-149, NCI-2012-02106, 1011004095, 1103-09, NCT01485874
Nintedanib and Capecitabine in Treating Patients with Refractory Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 265514, NCI-2015-00223, NCT02393755
Nintedanib in Treating Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Previously Treated with Bevacizumab
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00033060, NCI-2013-00455, NCT01669798
Nintedanib in Treating Patients with Advanced Non-small Cell Lung Cancer Who Have Failed up to Two Previous Chemotherapy Regimens
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 225512, NCI-2013-01618, NCT01948141
Nintedanib in Treating Patients with Advanced Esophageal, Gastroesophageal Junction, or Stomach Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-094, NCI-2014-01964, NCT02234596
Nintedanib in Treating Patients with Locally Advanced or Metastatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 259114, NCI-2015-00238, NCT02399215
Cisplatin, Docetaxel, and Nintedanib before Surgery in Treating Patients with Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0844, NCI-2014-02091, NCT02225405
Nintedanib in Treating Patients with Advanced Non-small Cell Lung Cancer and Mutations in Nintedanib-Targeted Genes
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201412116, NCI-2014-02625, 14-x346, NCT02299141
Start Over